Literature DB >> 8912954

Replication of a P50 auditory gating deficit in Australian patients with schizophrenia.

P B Ward1, L D Hoffer, B J Liebert, S V Catts, M O'Donnell, L E Adler.   

Abstract

Schizophrenic patients reportedly have a deficit in the control of sensitivity to auditory stimuli as shown by the P50 auditory evoked potential wave in a conditioning-testing paradigm that measures suppression of response to a repeated stimulus. Although this finding has been replicated by several US laboratories, one European group has not found differences between schizophrenic patients and normal control subjects. In the present study, investigators in the Schizophrenia Research Center at the Prince of Wales Hospital in Sydney, Australia, selected 22 normal control subjects, 11 acutely ill schizophrenic inpatients, and 11 clinically stable schizophrenic outpatients. Both schizophrenic groups were treated with similar doses of classical neuroleptic medications. Evoked potentials were recorded by an investigator from the US laboratory that initially reported the difference; five averages, each the response to 32 stimulus pairs, were recorded from each subject. The normal control subjects demonstrated significantly more suppression of the P50 response to the repeated stimuli than the schizophrenic groups, as previously reported. There were no significant changes in the suppression measure over the five trials. The suppression of the P50 wave by schizophrenic outpatients was somewhat greater than that by schizophrenic inpatients, but both schizophrenic groups had decreased suppression, compared with the normal subjects. The mean P50 suppression for five averages was successfully used in a logistic regression to classify subjects as normal or schizophrenic. This method was more accurate than attempts to classify subjects with only one average. The mean amplitude of the initial conditioning response did not differ between groups. Schizophrenic patients had slightly shorter mean latencies. There was no direct relationship of P50 suppression to measures of clinical psychopathology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912954     DOI: 10.1016/0165-1781(96)02876-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

Review 1.  Endophenotypes in schizophrenia: a selective review.

Authors:  Allyssa J Allen; Mélina E Griss; Bradley S Folley; Keith A Hawkins; Godfrey D Pearlson
Journal:  Schizophr Res       Date:  2009-02-15       Impact factor: 4.939

Review 2.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

Review 3.  Nicotine: abused substance and therapeutic agent.

Authors:  J Le Houezec
Journal:  J Psychiatry Neurosci       Date:  1998-03       Impact factor: 6.186

4.  Abnormal peripheral auditory asymmetry in schizophrenia.

Authors:  E Veuillet; N Georgieff; B Philibert; J Dalery; M Marie-Cardine; L Collet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

Review 5.  Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures.

Authors:  Bruce I Turetsky; Monica E Calkins; Gregory A Light; Ann Olincy; Allen D Radant; Neal R Swerdlow
Journal:  Schizophr Bull       Date:  2006-11-29       Impact factor: 9.306

Review 6.  Human and animal studies of schizophrenia-related gating deficits.

Authors:  G A Light; D L Braff
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 7.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 8.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

9.  Association between the 2-bp deletion polymorphism in the duplicated version of the alpha7 nicotinic receptor gene and P50 sensory gating.

Authors:  Rachel H Flomen; Madiha Shaikh; Muriel Walshe; Katja Schulze; Mei-Hua Hall; Marco Picchioni; Fruhling Rijsdijk; Timothea Toulopoulou; Eugenia Kravariti; Robin M Murray; Philip Asherson; Andrew J Makoff; Elvira Bramon
Journal:  Eur J Hum Genet       Date:  2012-05-16       Impact factor: 4.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.